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Abstract Radiotherapy (RT) after breast conserving
surgery (BCS) represents the standard for local control of
breast cancer (BC). However, variations in practice persist.
We aimed to characterize the rate of RT consideration (or
referral) after BCS and identify predictors in Quebec,
Canada, where universal health insurance is in place. A
historical prospective cohort study using the provincial
hospital discharge and medical services databases was
conducted. All women with incident, non-metastatic BC
(stages I–III) undergoing BCS (1998–2005) were identi-
fied. Odds ratios (ORs) and 95 % confidence intervals (CIs)
for RT consideration were estimated with a generalized
estimating equations regression model, adjusting for clus-
tering of patients within physicians. Of the 27,483 women
selected, 90 % were considered for RT and 84 % subse-
quently received it. Relative to women 50–69 years old,
younger and older women were less likely to be consid-
ered: ORs of 0.82 (95 % CI 0.73–0.93) and 0.10
(0.09–0.12), respectively. Emergency room visits and
hospitalizations unrelated to BC were associated with
decreased odds of RT consideration: 0.85 (0.76–0.94) and
0.83 (0.71–0.97). Women with regional BC considered for
chemotherapy were more likely to be considered for RT:
3.41 (2.83–4.11). RT consideration odds increased by 7 %
(OR of 1.07, 95 % CI 1.03–1.10) for every ten additional
BCSs performed by the surgeon in the prior year. Social
isolation, comorbidities, and greater distance to a referral
center lowered the odds. Demographic and clinical patient-
related risk factors, health service use, gaps in other aspects
of BC management, and surgeon’s experience predicted
RT consideration.
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NCCN National comprehensive cancer network
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MSSS Ministe`re de la Sante´ et des Services
sociaux
MED-E´CHO Maintenance et exploitation des donne´es
pour l’e´tude de la cliente`le hospitalie`re
IRB Institutional review board
CCI Charlson comorbidity Index
ER Emergency room visit
ICD International classification of diseases
DCTD Diffused connective tissue disease
COPD Chronic obstructive pulmonary disease
GEE Generalized estimating equation
CCSRI Canadian Cancer Society Research
Institute (CCSRI)
CIHR Canadian Institutes of Health Research
FRSQ Fonds de la recherche en Sante´ du Que´bec
Introduction
Variations in quality of care have been documented in
every aspect of breast cancer (BC) management, from
prevention to follow-up [8, 25, 30]. It is estimated that up
to 70 % of BC patients may not be receiving the proper
care for at least one component of their BC treatment [27].
In addition to affecting quality of life and health care costs,
these discrepancies have been proven to result in higher
recurrence rates and shorter survival [20, 37, 46]. Devia-
tions from best practices in BC management are not limited
to complex cases or difficult treatment schemas; they most
often concern basic, well-established evidence-based
standards of care [38].
Patients with high-risk non-metastatic BC who receive
radiotherapy (RT) after breast conserving surgery (BCS)
achieve significantly better local control [9, 12, 16]. The
addition of RT decreases the 5-year BC local recurrence
rate from 26 to 7 % [9], with a benefit that persists at
20 years of follow-up [16, 45]. In fact, the combination of
BCS and RT has been shown to provide cancer control
equivalent to mastectomy [15] and has therefore become
the standard method of treatment as it avoids the physio-
logical and psychological impact associated with mastec-
tomy. Consequently, BCS followed by RT has become the
standard of care according to guidelines for the manage-
ment of patients with high-risk non-metastatic BC [32].
Despite this evidence, some high-risk BC patients fail to
receive RT after BCS due to a variety of patient, physician,
and other factors [9]. A better understanding of the risk
factors leading to suboptimal local BC control is needed to
address this gap in cancer care quality. The universal health
insurance program in the province of Quebec (Canada) pro-
vides a unique opportunity to study barriers to optimal health
care, confounded to a lesser degree by socio-economic status
[14]. To receive RT in Quebec, a patient must be seen by a
radiation oncologist working at a designated referral center
(CRID) [18]. Failure to receive a referral to a radiation
oncologist may reflect lack of patient consideration for RT by
the treating physician and thus lack of RT receipt. The pri-
mary objectives of the present study were to characterize the
rate of guideline-appropriate consideration for RT in women
with BC (stages I–III), who underwent BCS between Jan 1,
1998 and Dec 31, 2005 in Quebec and to identify patient- and
physician-related factors that predict it.
Population and methods
Setting and data sources
The source population for this study consisted of Quebec
residents, covered by the provincial health insurance plan
(RAMQ) ([98 % of the province’s population of
[7.8 million). Data for this study was available from 1997
to 2007 and was acquired through anonymous linkage of
the following databases: (1) RAMQ’s registrants’ database,
which provides demographic and socioeconomic data
including the social isolation index (SSI) [35] for regis-
trants; (2) RAMQ’s medical services database, which
contains physician fee-for-service claims; and (3) Quebec’s
hospital abstract discharge database (MED-E´CHO), which
captures data on hospital admissions and discharge diag-
noses. MED-E´CHO is the data source for the Quebec
Tumor Registry, which was used to verify that all BC were
new incident cases. Appropriate ethical clearances were
obtained from the Institutional Review Board (IRB) at
McGill University and the Provincial Access to Informa-
tion Office.
Design and study population
A historical prospective cohort study design was used.
Women C18 years of age, which were diagnosed with
localized or regional BC in Quebec between Jan 1, 1998
and Dec 31 and underwent BCS within 6 months of
diagnosis, were identified from MED-E´CHO. To identify
these women, RAMQ procedure codes (Table 3) corre-
sponding to BCS and primary diagnostic codes [Interna-
tional Classification of Diseases, 9th edition, adapted for
Quebec (ICD-9-QC)] corresponding to a diagnosis for
localized or regional BC [28] (Table 4) were used. Women
entered the cohort in 1998 in order to ensure at least 1 year
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of medical service history prior to the BCS was available
for the selected patients. Women with in situ or metastatic
BC, those who received a mastectomy, passed away, or
became ineligible for medical insurance in the year after
diagnosis, were excluded from the study population.
Patients from insular or remote northern territories were
also excluded (Iles-de-la-Madeleine, Nord-du-Quebec &
Anticosti) on the premise that health care provision in these
regions differed too much from other parts of the province,
making them outliers.
Assessment of patient and surgeon characteristics
Patient and surgeon characteristics were assessed for the
year prior to the patient’s BCS. Age at diagnosis was cal-
culated using the patient’s date of birth, provided by the
registrants’ database. The residence of each patient was
classified as rural or urban if the second digit of her postal
code was 0 or not, in accordance with Canada Post Cor-
poration delivery service [41]. The driving distance
between the centroid of each patient’s forward sortation
area (first 3 characters of the postal code) and the nearest
designated center of excellence for breast care in Quebec
[18] was calculated in kilometers (km) using Google Maps.
The comorbidity profile of each patient was assessed using
the Charlson comorbidity index (CCI), calculated using the
Enhanced ICD-9 coding algorithm [36] using the medical
services database. The ICD-9 codes for BC were removed
from the algorithm index since as all women in the cohort
have BC by default. Visits to the emergency room (ER)
were determined using RAMQ establishment code ‘‘0X7,’’
corresponding to ‘‘emergency department’’ in the medical
services database. The number and type (over-night or day
cases) of hospitalizations according to surgery was deter-
mined from the MED-E´CHO database. Conditions con-
traindicative for RT such as diffused connective tissue
disease (DCTD), chronic obstructive pulmonary disease
(COPD), or pregnancy were assessed from the medical
services database using selected ICD-9 codes or RAMQ
procedure codes relating to this condition (Tables 3, 4).
Chemotherapy consultation and receipt were identified
through the presence of claims with RAMQ procedure
codes corresponding to either consultation for chemother-
apy or treatment in the medical services database up to
4 months after BCS (Table 3 ). The stage of BC was
determined using topography and morphology codes in the
hospital discharge database as previously published [28].
Surgeon and hospital characteristics included number of
BCSs performed prior to the selected woman’s surgery.
RAMQ procedure codes were used to determine the number
and type of BC surgeries from the medical services database
(Table 3). Surgeons were classified as either general sur-
geons (RAMQ specialty code of 24) or ‘‘other’’ surgeons.
Assessment of outcome
RT consideration was ascertained through the presence of
claims with RAMQ procedure codes corresponding to
either consultation with a radiation oncologist (RAMQ
physician specialty code of 30) or treatment in the med-
ical services database up to 1 year after diagnosis, as per
guideline recommendations [34] (Table 4). It was
assumed that if a woman received a consultation for RT
but no subsequent treatment, she had been considered for
therapy.
Data analysis
A generalized estimating equation (GEE) model [26] with
logit link and exchangeable working correlation structure
was constructed to assess the association between predictor
variables and RT consideration after taking into account
the clustering of patients’ characteristics treated by the
same physician (i.e., physician was repeated over patients).
The distribution was assumed to be binomial. Univariate
analysis was performed to assess the unadjusted associa-
tions between each predictor and the outcome. Subse-
quently, all predictors were included in the GEE model.
Collinearity between variables was assessed via a Pearson
correlation matrix and, as a result, residence was left out of
the model due to its correlation (coefficient of C0.5) with
distance to hospital. In addition, interaction terms ‘‘con-
sidered for chemotherapy’’ and ‘‘cancer stage’’ were tested
based on the premise that having been considered for
chemotherapy and patient’s BC stage may have influenced
RT consideration but were found not to be significant.
Subsequently, stepwise selection of significant variables
was performed. The working correlation of the final GEE
model was 0.030. All P values are for two-tailed tests with
statistical significance defined as P B 0.05. SAS software




In total, 42,800 women were diagnosed with incident BC in
Quebec between Jan 1, 1998 and Dec 31, 2005. Of these,
15,317 (35.8 %) were excluded because they had in situ
(N = 4,549) or metastatic BC diagnosis (N = 215), died
(N = 2,443) or became ineligible for medical insurance
within 1 year of diagnosis (N = 53), were treated with
mastectomy (N = 5,922) or did not have a breast surgery at
all (N = 2,075), or lived in remote outlier regions
(N = 60). The remaining 27,483 women comprised the
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study population. All of these women were diagnosed with
non-metastatic BC (stages I–III) and treated with BCS
within 6 months of diagnosis. Mean age was 60 years
(range: 18–99), 72 % of women had localized BC, 77 %
did not have major comorbidities (CCI of 0) (Table 1).
Demographically, 83 % of women lived in urban areas,
70 % of women lived within 20 km from a designated
referral center, and 56 % of women were not considered
socially isolated (SSI B 3). Less than 1 % of the cohort
had DCTD or pregnancy during treatment, while 10 % had
COPD. About 6 and 75 % of women had an over-night
hospital admission or an ER visit, respectively, both
unrelated to their BC in the year prior to BCS.
Physician characteristics
On average, women saw 4 physicians (range: 1–21) for
their BC in the year after their BCS. Of the surgeons who
performed this cohort’s BCSs, 99 % were general sur-
geons. The latter performed an average of 52 BCS (range:
0–279) in the prior year.
Use of RT in Quebec
Overall, 24,764 (90 %) of women with incident, non-
metastatic BC having undergone BCS were considered for
RT (i.e., received a consultation or referral) within a year.
Of those, 84 % subsequently received RT.
Table 1 Baseline demographic and clinical characteristics of patients
(N = 27,483)
Patient characteristics Value





Mean (SD) 59.5 (12.5)
Range 18–99
Year of BCS [n (%)]
B2000 6,893 (25.1)
[2001 20,576 (74.9)




Less isolated (values 1–3) 15,242 (55.5)

















ER visits unrelated to BCc [n (%)]
Yes 20,615 (75.0)
No 4,376 (15.9)
Overnight hospitalizations unrelated to BCc [n (%)]
Yes 1,509 (5.5)
No 25,974 (94.5)
Contraindicated for RT conditionsc [n (%)]
Diffuse diseases of connective tissue 71 (0.3)
Chronic pulmonary disease 2,713 (9.9)
Pregnancy 35 (0.1)
RT statusd [n (%)]
Had consult and started 23,205 (84.4)
Had consult but did not start 1,559 (5.7)
Had no consult 2,719 (9.9)
Chemotherapy statuse [n (%)]
Had consult and started 6,928 (25.2)
Table 1 continued
Patient characteristics Value
Had consult but did not start 7,016 (25.5)
No consult 13,539 (49.3)
Number of BC treating physiciansd
Mean (SD) 4.2 (2.3)
Range 1–21
Surgeon’s specialityc [n (%)]
General surgery 27,393 (99.7)
Other surgical specialties 90 (0.3)
Surgeon’s case volumec
Mean number of BCSs (SD) 51.3 (51.8)
Range 0–279
SD Standard deviation, BCS breast conserving surgery, SII social iso-
lation index, N/A unavailable, CCI Charlson comorbidity index, ER
emergency room, BC breast cancer, RT radiotherapy
a SII was not available for a small subset of the population
b ICD-9 codes for BC were removed from the coding algorithm for the
CCI since as all women in the cohort had BC by default
c Assessed in the year prior to BCS
d Assessed in the year after BCS
e Assessed up to 4 months after BCS
400 Breast Cancer Res Treat (2013) 140:397–405
123
Factors associated with RT consideration
Results of the statistical analysis of factors associated with
consideration of postoperative RT are described in Table 2.
Relative to the largest age group (50–69 years), odds ratios
(ORs) for groups \50, 70–79, and C80 years were 0.82
[confidence interval (CI) 0.73, 0.93], 0.55 (0.48, 0.61), and
0.10 (0.09, 0.12), respectively. Relative to those living
close to a designated RT center, those living far had a
significantly less likely to be considered for RT, OR 0.96
(0.94–0.97) per 20 km increase in distance. Less socially
isolated women (SII of 1–3) were more likely to be con-
sidered for RT, OR 1.16 (1.06–1.26) compared to more
socially isolated ones (SII of 4–5). Relative to women with
CCI of 0, those with CCI of C3 (moderate to severe
comorbidities) were less likely to be considered for RT, OR
0.79 (0.62–1.00). Women with overnight hospitalizations
or ER visits, both unrelated to BC in the past year, were
also less likely to be considered for RT, compared to those
without, OR 0.83 (0.71–0.98) and 0.85 (0.76–0.94),
respectively. Women with localized and regional BC that
were considered for chemotherapy were also more likely to
be considered for RT: ORs 2.27 (1.96–2.64) and 3.41
(2.83–4.11), respectively. Surgeon’s volume of BCS in the
previous year significantly predicted RT consideration. A
7 % increase in the odds of being considered for RT was
seen for every ten additional BCS performed in the pre-
vious year by the treating surgeon: OR 1.07 (1.03–1.10).
Discussion
In this large population-based study of Quebec women with
incident, non-metastatic BC (stages I–III), we found that 1
in 10 women undergoing BCS were not considered for RT.
Lack of consideration for RT was associated with age
extremes (younger and elderly patients being significantly
less likely to be considered), social isolation, CCI, distance
from a designated RT center, and certain health service use
indicators such as ER visits or hospitalizations in the year
before BCS. We also found that gaps in other aspects of BC
care, such as lack of consideration for chemotherapy (in
patients with stage III disease) or surgeon’s volume of BCS
were also strongly associated with lack of RT
consideration.
A substantial variation in the use of RT after BCS has
been reported by existing studies, ranging 57–95 % based
on geographical region and study population [7, 11, 23,
44]. However, many of these studies have mostly explored
the rate of RT receipt as opposed to rate of RT consider-
ation, omitted physician-related factors [44], have been
limited to patients with early-stage BC [11, 47], carcinoma
in situ [1, 13], smaller sample sizes [7, 23, 33, 44], included
only older patients [39, 40]. The rate of RT receipt
observed in this study (84 %) is similar to studies using
insured populations. However, less is known about the
impact of treatment decisions by the physician on access to
RT, especially for young or middle-aged women with
locally advanced BC. We found only three studies [3, 33,
44] that evaluated the rate of RT consideration. They
reported values in range of 77–94 %, which were consis-
tent with our study.
Older age [2, 11], distance to RT centers [31], rural,
isolated, ethnic, or unmarried status [3], and the presence
of comorbidities [2] have been consistently reported as a
risk factors for RT non-receipt across the literature. How-
ever, the link between RT non-consideration and these
demographic and clinical factors remains poorly under-
stood. It may reflect a certain level of physician non-
compliance with practice guidelines in addition to patients’
treatment preferences or patients’ barriers to access of
health care such as distance, age, or socioeconomic status.
We observed that women less than 50 years were less
likely to be considered for RT compared to the 50–69 age
group, which is concerning since these women have a
greater chance of recurrence, longer life-expectancy, and
have been shown to be less persistent and adherent to
future therapy such as adjuvant hormonal therapy [21].
Younger women with cancer have unique medical, psy-
chosocial, and economic challenges that might be
decreasing their odds of consideration for treatments such
as RT by some physicians [5]. Further research is required
to understand the challenges unique to this population.
Our study found that healthcare service utilization
indicators such as overnight hospitalizations and ER visits,
both unrelated to BC, in the year before BCS, were asso-
ciated with a lower chance of being considered for RT after
BCS after adjustment for comorbidities. Such indicators
might be reflective of additional comorbidities and/or lack
of affiliation with a family physician resulting in a lack of
continuity and comprehensiveness of care [29]. In addition,
a tendency to underestimate comorbidity in claims data has
been previously shown [10] and this may have lowered the
explanatory power of the CCI index in this study. This may
explain why women with such health service utilization
indicators were in a worse position for being considered for
RT, compared to women without such indicators. Efforts to
increase continuity of care may improve treatment out-
comes in BC care.
Variations in quality of care have been documented in
other aspects of cancer care from prevention to manage-
ment and follow-up and stem from complex interplay of
patient, provider, and institutional factors [8, 25, 30]. In
this study, we observed that women with stage III disease
that were considered for chemotherapy had stronger odds
for RT consideration compared to those not considered for
Breast Cancer Res Treat (2013) 140:397–405 401
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chemotherapy even after adjusting for clustering of
patients within the same physician. This may imply that
gaps in one aspect of BC care may increase the odds for
gaps in other aspects of BC care such as RT consideration
resulting in worse outcomes after a diagnosis of cancer for
some patients and elevated health care spending. These
gaps represent factors that are potentially modifiable.
Implementation of electronic medical records-based tools
[42], increasing continuity of care and telemedicine [43]
can help primary care providers keep track of recom-
mended treatments tailed to each individual patient’s
health status and insure proper continuum of cancer care
for his or her patients in a cost-effective manner. We
further demonstrated that women who lived farther away
from designated RT centers were significantly less likely
to be considered for RT (4 % decrease for every 20 km
Table 2 Patient-related demographic and clinical predictors of radiotherapy consideration
Predictors % considered for RTa No. of patients Univariate analysisb Multivariate GEE analysisc
OR 95 % CI P OR 95 % CI P
Age (years)
\50 93.3 6,189 0.97 0.86–1.09 0.600 0.82 0.73–0.93 0.002
50–69 93.6 14,958 1.00 Referent 1.00 Referent
70–79 87.9 4,622 0.45 0.41–0.50 \0.001 0.55 0.48–0.61 \0.001
C80 53.9 1,714 0.07 0.07–0.08 \0.001 0.10 0.09–0.12 \0.001
Social isolation index
Less isolated (values 1–3) 91.2 15,242 1.28 1.18–1.39 \0.001 1.16 1.06–1.26 \0.001
More isolated (values 4–5) 89.1 11,345 1.00 Referent 0.006 1.00 Referent
N/A 84.2 896 0.65 0.54–0.79 \0.001 0.74 0.61–0.89 0.001
Charlson comorbidity index
0 (none) 91.2 20,615 1.00 Referent 1.00 Referent
1 88.0 4,376 0.71 0.64–0.78 \0.001 0.93 0.84–1.04 0.191
2 86.5 1,430 0.66 0.56–0.77 \0.001 0.86 0.71–1.04 0.123
C3 (moderate or severe) 83.0 1,062 0.46 0.37–0.57 \0.001 0.79 0.62–1.00 0.046
Hospitalizations, unrelated to BC, in year before BCS
Over-night hospitalization(s) 83.0 1,509 0.51 0.44–0.59 \0.001 0.83 0.71–0.98 0.024
No over-night hospitalizations 90.5 25,974 1.00 Referent 1.00 Referent
ER visits, unrelated to BC, in year before BCS
Yes 86.9 6,868 0.65 0.59–0.70 \0.001 0.85 0.76–0.94 0.002
No 91.2 20,615 1.00 Referent 1.00 Referent
Chemotherapy and tumor stage
No consult, localized cancer 84.4 10,920 1.00 Referent 1.00 Referent
Had consult, localized cancer 92.7 8,981 2.36 2.14–2.59 \0.001 2.27 1.96–2.64 \0.001
No consult, regional cancer 94.3 2,619 3.09 2.60–3.67 \0.001 2.22 1.84–2.67 \0.001
Had consult, regional cancer 95.7 4,963 4.12 3.56–4.77 \0.001 3.41 2.83–4.11 \0.001
Surgeon’s case volume in previous year Mean SD Univariate analysisb Multivariate GEE analysisc
OR 95 % CI P OR 95 % CI P
Per 10 breast surgeries increase 52.3 51.9 1.05 1.04–1.06 \0.001 1.07 1.03–1.10 \0.001
Distance to designated center for excellence in breast Care (km)
Per 20 km increase 29.6 58.4 0.97 0.96–0.98 \0.001 0.96 0.94–0.97 \0.001
CI Confidence interval, OR odds ratio, ER emergency room, N/A missing or unavailable data, GEE generalized estimating equations, P P value
a Included were patients who received a consultation for radiotherapy up to 1 year after diagnosis, as per guideline recommendations
b Unadjusted associations were assessed using bivariate analysis between outcome and characteristics
c Multivariate logistic regression using a GEE model with an exchangeable working correlation (value of 0.019) to account for clustering of
patients (N = 27,483) within physicians (N = 424) was used to assess associations between predictors adjusted for pre-existing conditions,
residence, year of diagnosis, stage of tumor, and surgeon’s specialty. The mean cluster size was 64.7 patients, range: 1–796
402 Breast Cancer Res Treat (2013) 140:397–405
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increase in distance) after adjusting for other covariates. It
is well known that women living further from RT centers
have a lower likelihood of receiving RT [31], but an
association between distance and lack of consideration
suggests that distance might be a barrier not only to
patients but also to physicians as well when it comes to
providing a referral. During a self-administered survey of
physician referral practices for hereditary breast cancer,
conducted by Koil et al., rural-practice physicians reported
several barriers including ‘‘distance of services,’’ ‘‘lack of
awareness of services,’’ ‘‘lack of effective risk reduction or
clinical management,’’ and ‘‘patients not interested’’
(P \ 0.05) [24]. Telemedicine could aid in providing
referrals for RT to eligible patients, who currently do not
get considered due to distance barriers.
Similar to other studies [22], we found that surgeons
with higher volume of BCSs were significantly more likely
to comply with guidelines and provide a consultation for
RT compared to lower volume surgeons (7 % increase for
every 10 additional lumpectomies). We observed a similar
relationship between high-volume centers and treatment
outcomes (results not shown). Birkmeyer et al. [4] found
that high-volume hospitals have better outcomes in large
part because patients at these hospitals are more likely to
be treated by high-volume surgeons and that standards
based on surgeon volume as well as hospital volume would
be more useful in directing patients to the providers who
are likely to achieve the best outcomes. They hypothesized
that improving surgeon’s decision-making skills could
simply be achieved by ‘‘practice’’—clinical judgment and
technical skill that are achieved only by surgeons who
perform a specific procedure with sufficient frequency [4].
Harmon et al. [19] showed that medium-volume surgeons
achieved results equivalent to high-volume surgeons when
they operated in high- or medium-volume hospitals. Thus,
high-volume hospitals could be allowing greater access to
specialized teams in all aspects of patient care and the
development of clinical pathways. Continuous education
programs, redistribution of cases among a smaller number
of surgeons in high-volume hospitals, and performance
evaluations could ensure that surgeons meet certain prac-
tice-based competency levels or stay up to date with the
most recent innovations in cancer care.
This study has several limitations. Similar to other
studies that use administrative claims, there was no infor-
mation on provider’s reasoning or on tumor factors such as
size of margins, histology grade, and the presence of
comedo necrosis. The availability of prior data was not
sufficient to allow us to control for patients with childhood
Hodgkin Lymphoma, a contraindication for RT due to prior
RT. However, given the low incidence rate of this disease
in the Canadian population (3 per 100,000) [6], had we
controlled for this, at most one patient would have been
excluded. The CCI might underestimate the true patient
comorbidity profile because the coding algorithm flags
only diagnoses arising from comorbidities severe enough to
result in medical service utilization. Nevertheless, this is
the best proxy for this variable. Procedures not billed for by
physicians by error and procedures performed at private
clinics (an exception in Quebec) were missing. The
strengths of our study lie in the fact that the entire popu-
lation of women undergoing BCS in Quebec was captured
and that the data are robust: physicians are paid on a fee-
for-service basis, and completeness and accuracy of
reporting have monetary incentives attached [17].
Conclusion
We found that 1 in 10 women with high-risk, non-meta-
static BC that underwent BCS in Quebec between 1998 and
2005 did not get considered for guideline-recommended
RT. The younger and elderly women, socially isolated or
those who lived far from designated RT centers, those with
multiple comorbidities, hospital admissions, or ER visits in
the past year were significantly less likely to be considered
for RT. Women with stage III BC not considered for
chemotherapy were also less likely to be considered for
RT, suggesting that gaps in one aspect of cancer care
quality may increase the odds of gaps in other aspects of
treatment. Surgeon case volume in the previous year was
associated with greater odds of RT consideration.
Strengthening continuity of care and implementing tools
such as electronic medical records and telemedicine could
minimize some disparities and ensure timely delivery of
care. Further investigation is required to better understand
the relationship between surgeon volume and compliance
with guidelines of care.
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